Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunohistochemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    714 result(s) found for: Immunohistochemistry. Displaying page 4 of 36.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000699-40 Sponsor Protocol Number: BR55-102 Start Date*: 2012-07-26
    Sponsor Name:BRACCO IMAGING
    Full Title: A Study of BR55 in Contrast Enhanced Ultrasound Imaging in Patients with Ovarian and Breast Cancer.
    Medical condition: Patients with ovarian or breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003372-37 Sponsor Protocol Number: ET11-072 Start Date*: 2014-06-04
    Sponsor Name:CENTRE LEON BERARD
    Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre...
    Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001120-54 Sponsor Protocol Number: SQ167015 Start Date*: 2016-07-25
    Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust
    Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?
    Medical condition: Recurrent miscarriage
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002275-40 Sponsor Protocol Number: 2006-002275-40 Start Date*: 2007-01-24
    Sponsor Name:Uppsala University Hospital, Dept. of Medical Sciences
    Full Title: Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids
    Medical condition: Metastasizing ileal/coecal carcinoids (WHO ICD-10 code: C17.9)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004898-16 Sponsor Protocol Number: V_1 Start Date*: 2015-05-27
    Sponsor Name:Medizinische Universität Wien
    Full Title: A study to investigate (R)-11C-verapamil PET as a predictive biomarker for epilepsy surgery outcome
    Medical condition: temporal lobe epilepsy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10043209 Temporal lobe epilepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001806-40 Sponsor Protocol Number: STATLiver2019 Start Date*: 2019-09-03
    Sponsor Name:Afsnit 360, Gastroenheden
    Full Title: Statins for prevention of disease progression and hospitalization in Liver Cirrhosis: A multi-center, randomized, double blind, placebo-controlled trial. The STATLiver Trial.
    Medical condition: Cirrhosis of the liver
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004284-51 Sponsor Protocol Number: ESR-18-14159 Start Date*: 2020-04-14
    Sponsor Name:Amsterdam UMC, VU University Medical Center
    Full Title: An exploratory study of durvalumab (MEDI4736) uptake during concurrent chemoradiotherapy in stage III NSCLC patients using 89Zr-labeled durvalumab PET
    Medical condition: Lung cancer, NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002364-27 Sponsor Protocol Number: ABCSG_52 Start Date*: 2020-04-09
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer
    Medical condition: HER2-positive early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003481-41 Sponsor Protocol Number: FM-12-B01 Start Date*: 2013-02-19
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)
    Medical condition: Patients with HER2-negative, early invasive unilateral breast cancer who are at risk of disease recurrence and suitable for neoadjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006283 Breast neoplasm malignant female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002854-19 Sponsor Protocol Number: S58827 Start Date*: 2017-08-03
    Sponsor Name:UZ Leuven
    Full Title: Neoadjuvant degarelix +/- apalutamide (ARN-509) followed by radical prostatectomy for intermediate and high-risk prostate cancer: a randomized, placebo-controlled trial.
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020835-38 Sponsor Protocol Number: IEOS550310 Start Date*: 2011-09-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: “A phase II study of cisplatin plus cyclophospamide for patients with previously treated, advanced, triple receptor negative breast cancer”
    Medical condition: Advanced, triple receptor negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005666-36 Sponsor Protocol Number: IBCSG 22-00 Start Date*: 2009-12-07
    Sponsor Name:International Breast Cancer Study Group
    Full Title: Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer Maintenance Chemotherapy in Hormone Non-...
    Medical condition: Histologically proven ER-negative and PgRnegative breast cancer with either a total mastectomy with axillary clearance or a lesser procedure with axillary lymph node dissection or sentinel node pro...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004052-15 Sponsor Protocol Number: 202000570 Start Date*: 2021-11-24
    Sponsor Name:University Medical Center Groningen
    Full Title: ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with or without platinum-based chemotherapy
    Medical condition: Patients with metastatic solid tumors, where clinical data has shown a rationale for ICI therapy with or without platinum-based chemotherapy, will be included in this study.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002493-13 Sponsor Protocol Number: M16BRC Start Date*: 2016-09-15
    Sponsor Name:NKI-AVL
    Full Title: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy
    Medical condition: High risk breast cancer (stage III), BRCA1-like
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003389-25 Sponsor Protocol Number: CC-5013-MCL-002 Start Date*: 2011-04-11
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
    Medical condition: Patients with mantle cell lymphoma are refractory to their regimen or have relapsed once or up to three times.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) DK (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002465-35 Sponsor Protocol Number: B3461028 Start Date*: 2014-04-07
    Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company
    Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000086-74 Sponsor Protocol Number: 1559-HNCG Start Date*: 2017-10-05
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM"
    Medical condition: Recurrent/metastatic squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005617-14 Sponsor Protocol Number: CLEE011Q12101 Start Date*: 2022-10-10
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblast...
    Medical condition: relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004280-32 Sponsor Protocol Number: AG10-301 Start Date*: 2019-05-10
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001060-38 Sponsor Protocol Number: NLG-MCL7 Start Date*: 2018-02-21
    Sponsor Name:Nordic Lymphoma Group
    Full Title: Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma.
    Medical condition: Relapsed/refractory mantle cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Completed) DK (Completed) FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 07:07:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA